Announcements and Notices - [Other - Business Update]

Antengene Corporation Limited operates as a specialty pharmaceutical company. The Company produces innovative drugs, selinexor, eltanexor, verdinexor, and other products. Antengene provides its services throughout China.

Voluntary Announcement
Xpovio Approved In Malaysia For A New Indication
In Diffuse Large B-Cell Lymphoma

Announcements and Notices - [Terms of Reference of the Nomination Committee]

Nomination And Corporate Governance Committee - Terms Of Reference

Voluntary Announcement
Xpovio Approved In Hong Kong For Two Additional
Indications In Multiple Myeloma And Diffuse Large B-Cell
Lymphoma

Voluntary Announcement
Ind Approval In China For Phase Ib/Ii Study Of
Atg-022 In Combination With Keytruda (Pembrolizumab) 
Chemotherapy

Financial Statements/ESG Information - [Interim/Half-Year Report]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Antengene (6996 HK)

Voluntary Announcement Xpovio Approved In Malaysia For A New Indication In Diffuse Large B-Cell Lymphoma

Nomination And Corporate Governance Committee - Terms Of Reference

Voluntary Announcement Xpovio Approved In Hong Kong For Two Additional Indications In Multiple Myeloma And Diffuse Large B-Cell Lymphoma

Voluntary Announcement Ind Approval In China For Phase Ib/Ii Study Of Atg-022 In Combination With Keytruda (Pembrolizumab) Chemotherapy

2025 Interim Report

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)